CHMP4C anticorps (AA 1-233) (HRP)

N° du produit ABIN7147528

Détail du produit anti-CHMP4C anticorps (HRP)

Antigène: CHMP4C (Charged Multivesicular Body Protein 4C (CHMP4C))

Épitope: AA 1-233

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CHMP4C est conjugé à/à la HRP

Application: ELISA

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Charged multivesicular body protein 4c protein (1-233AA)

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur CHMP4C

Antigène: CHMP4C (Charged Multivesicular Body Protein 4C (CHMP4C))

Autre désignation: CHMP4C (CHMP4C Produits)

Synonymes: anticorps 2010012P02Rik, anticorps 2210015K02Rik, anticorps 2310010I16Rik, anticorps Shax3, anticorps Snf7-3, anticorps SNF7-3, anticorps VPS32C, anticorps zgc:110173, anticorps CHMP4c, anticorps chmp4c, anticorps charged multivesicular body protein 4C, anticorps charged multivesicular body protein 4C L homeolog, anticorps Chmp4c, anticorps CHMP4C, anticorps chmp4c, anticorps chmp4c.L

Sujet:

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: upon phosphorylation by AURKB, together with ZFYVE19/ANCHR, retains abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation from ANCHR and VPS4 and subsequent abscission (PubMed:22422861, PubMed:24814515). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413).

Aliases: Charged multivesicular body protein 4c antibody, CHM4C_HUMAN antibody, CHMP4c antibody, Chromatin-modifying protein 4c antibody, hSnf7-3 antibody, hVps32-3 antibody, SHAX3 antibody, SNF7 homolog associated with Alix 3 antibody, SNF7-3 antibody, Vacuolar protein sorting-associated protein 32-3 antibody, Vps32-3 antibody

UniProt: Q96CF2